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ORIGINAL ARTICLE
Tumor–stroma ratio predicts recurrence in patients with colon cancer treated
with neoadjuvant chemotherapy
Torben Frøstrup Hansena,b, Sanne Kjær-Frifeldta,b, Jan Lindebjerga,b, Søren Rafael Rafaelsena,b,
Lars Henrik Jensena,b, Anders Jakobsena,b and Flemming Brandt Sørensena,b,c
aDanish Colorectal Cancer Center South, Vejle Hospital, Vejle, Denmark; bInstitute of Regional Health Research, University of Southern
Denmark, Odense, Denmark; cUniversity Institute of Pathology, Aarhus University Hospital, Aarhus, Denmark
ABSTRACT
Background: Neoadjuvant chemotherapy represents a new treatment approach to locally advanced
colon cancer. The aim of this study was to analyze the ability of tumor–stroma ratio (TSR) to predict
disease recurrence in patients with locally advanced colon cancer treated with neoadjuvant
chemotherapy.
Material and methods: This study included 65 patients with colon cancer treated with neoadjuvant
chemotherapy in a phase II trial. All patients were planned for three cycles of capecitabine and oxali-
platin before surgery. Hematoxylin and eosin stained tissue sections from surgically resected primary
tumors were sampled and analyzed by conventional microscopy. Patients were divided into stroma-
high (>50%, i.e. TSR low) and stroma-low (50%, i.e. TSR high) for the comparison with clinical data.
Results: A low TSR was found in 47% of the surgically resected primary tumors and correlated to a sig-
nificantly higher T- and N-category compared, to tumors with a high TSR (p< .01). A low TSR was also
significantly associated with disease recurrence (p¼ .008), translating into significant differences in dis-
ease free survival (DFS) and overall survival, p< .002. The 5-year DFS rate for patients with a low TSR
was 55%, compared to 94% in the group of patients with a high TSR.
Conclusions: TSR assessed in the surgically resected primary tumor from patients with locally
advanced colon cancer treated with neoadjuvant chemotherapy provides prognostic value and may
serve as a relevant parameter in selecting patients for post-operative treatment.
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Introduction
A considerable fraction (20–50%) of patients operated for
stage II and III colon cancer experience disease recurrence,
typically within two or three years after surgery [1]. Early
identification of the patients at risk is desirable and could
spare many from ineffective adjuvant chemotherapy [2].
Multiple putative prognostic markers have been assessed
in this context over the last decades. Only a few, however,
are considered suitable for guiding the clinicians and the
patients in the decision on adjuvant chemotherapy [3].
Assessing the ratio between adenocarcinoma cells and stro-
mal cells in the primary tumor, i.e. tumor–stroma ratio (TSR),
has gained increasing interest over the last 10 years due to
the simplicity and the potential clinical value of this marker.
It is a fast and cost efficient estimate based on routine diag-
nostic hematoxylin and eosin (H&E) stained tissue sections.
Most studies regarding the technical aspects of TSR scoring
provide kappa-values pointing to at least moderate, but
mostly substantial and even optimal reproducibility. The cur-
rent literature unanimously points toward TSR as a prognos-
tic marker in patients operated for colon cancer [4–10],
although results from larger population based cohorts are
still awaited. A high amount of stroma (low TSR) is related to
a poor prognosis and may also influence the delivery of che-
motherapeutics to the cancer cells.
Neoadjuvant chemotherapy is currently being investigated
in patients with locally advanced colon cancer and may rep-
resent a new treatment approach ensuring early systemic
treatment of minimal metastatic disease [11]. The initial
phase II experience indicates that a substantial proportion of
these patients may convert to a low risk status at the time of
operation, eliminating the need for adjuvant chemotherapy
[12]. Whether TSR after exposure to neoadjuvant chemother-
apy still holds prognostic value after the operation has never
been investigated before.
The aim of this study was to analyze the ability of TSR to
predict disease recurrence in patients with locally advanced
colon cancer treated with neoadjuvant chemotherapy.
Material and methods
Reporting in this study is in accordance with the REMARK cri-
teria [13].
CONTACT Torben Frøstrup Hansen torben.hansen@rsyd.dk, torbenhansen01@hotmail.com Department of Oncology, Vejle Hospital, Beriderbakken 4, 7100
Vejle, Denmark
 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any
way.
ACTA ONCOLOGICA, 2018
VOL. 57, NO. 4, 528–533
https://doi.org/10.1080/0284186X.2017.1385841
Study population
This translational study refers to a previous phase II trial of
neoadjuvant chemotherapy in patients with locally advanced
colon cancer [12]. The present study population represents
65 of the 71 patients who completed neoadjuvant chemo-
therapy followed by operation between August 2010 and
September 2013. The reasons for excluding six patients were
lack of tissue specimens in five cases and death a few days
after surgery in one case. All patients were diagnosed with
locally advanced, resectable colon cancer as detected by
computed tomography (CT) scans. Patients with documented
wild-type KRAS, BRAF and PIK3CA status received supplemen-
tal panitumumab, while patients with any mutation in the
above genes, or unknown mutational status, received neoad-
juvant chemotherapy only. All patients were 18 years, of
performance status (PS) 2 and had a T3 tumor with extra-
mural tumor invasion (ETI)> 5mm or a T4 tumor based on
CT scans. Selection criteria and follow-up have previously
been specified [12]. Patients were followed according to the
protocol for up to three years post-operatively. This period
was extended to five years for the present study to include
survival data (dead/alive) and histopathologically verified
recurrence (yes/no) of all included patients. Data were
recorded according to good clinical practice. The clinical
study, as well as the present translational research was
approved by the Regional Scientific Ethical Committee and
the Danish Data Protection Agency (S-20100014 and S-
20160031) and written informed consent was obtained from
all patients enrolled in the clinical study (ClinicalTrials.gov
NCT01108107). The tissue used for research was confirmed
not to be refused in the Danish Registry of Human Tissue
Utilisation.
CT scanning
CT scanning was performed using a 64-channel multidetec-
tor. Effective dose: approximately 8–9 mSv. Images were
obtained with breath-hold technique after intravenous injec-
tion of iomeprol (Iomeron, Bracco, Milan, Italy). Three mm CT
images were transferred to and stored within the Picture and
Archive Communication System (PACS). The CT images were
evaluated by a certified subspecialist in abdominal radiology.
Multiplanar reconstruction was performed on the PACS.
Treatment
Treatment consisted of neoadjuvant capecitabine 1000mg/m2
orally twice daily on days 1 through 14 (28 doses) in a 21-day
cycle, and oxaliplatin 130mg/m2 as a two-hour intravenous
infusion on day 1. Panitumumab 9mg/kg on day 1 of the 21-
day cycle was added to the neoadjuvant treatment for
patients with wild-type mutational status. Tumor resection
was performed three weeks after the last cycle of neoadjuvant
chemotherapy. Patients fulfilling the criteria for adjuvant
chemotherapy according to the Danish Colorectal Cancer
Group (DCCG) criteria (http://dccg.dk/retningslinjer/20150806/
2015_AdjKemoColon.pdf) (lymph node metastases, pT4 tumor,
acute surgery due to bowel obstruction, neuronal or vascular
invasion, high malignancy grade, less than 12 lymph nodes
removed) received an additional five cycles of the same
chemotherapy regimen. Patients not fulfilling the criteria (con-
verted from a high risk group requiring adjuvant chemother-
apy to low risk not requiring additional treatment) received
no further treatment. This conversion rate and tumor regres-
sion grade (TRG) as evaluated on the operative specimens
according to Mandard et al.’s [14] were used to estimate the
effect of neoadjuvant chemotherapy. This routine estimation
was performed by one observer. The TRG scores spanned
from 1, i.e. pathological complete response with no residual
tumor, to 5, referring to no response. All patients were fol-
lowed as previously specified [12].
Table 1. Clinical and pathoanatomic characteristics, N¼ 65.
Baseline After resection
Characteristics N (%) Characteristics N (%)
Gender Perforation
Male 35 (54) Yes 7 (11)
Female 30 (46) No 58 (89)
Age (years) Fixation
Mean, SD 66, 11 Yes 18 (28)
Range 39–85 No 47 (72)
>Mean 37 (57) Histology
Mean 28 (43) Adenocarcinoma 51 (78)
T category Mucinous 10 (15)
T3 ETI >5mm 56 (86) Othera 4 (6)
T4 9 (14) Malignancy grade
Lymph node status 1þ 2 39 (60)
N0 1 (2) 3 18 (28)
N1–2 64 (98) Not evaluable 8 (12)
Localization Perineural invasion
Right 36 (55) Yes 8 (12)
Left 29 (45) No 57 (88)
ECOG PS Vascular invasion
0 33 (51) Yes 19 (29)
1 32 (49) No 44 (68)
Mutations Not evaluable 2 (3)
KRAS Tumor budding
Wild-type 50 (77) Yes 9 (14)
Mutated 11 (17) No 54 (83)
Unknown 4 (6) Not evaluable 2 (3)
BRAF MSI status
Wild-type 42 (65) MSS 46 (71)
Mutated 17 (26) MSI 17 (26)
Unknown 6 (9) Not evaluable 2 (3)
PIK3CA pT category
Wild-type 50 (77) pT0 2 (3)
Mutated 8 (12) pT1 0 (0)
Unknown 7 (11) pT2 11 (17)
KRAS, BRAF, PIK3CA pT3 42 (65)
All wild-type 29 (45) pT4 10 (15)
1 gene mutated 29 (45) Lymph nodes removed
Unknown 7 (11) Mean 33
Range 6–86
pN category
pN0 42 (65)
pN1 15 (23)
pN2 8 (12)
Risk group conversionb
Yes 29 (45)
No 36 (55)
ECOG PS: Eastern Cooperative Oncology Group performance status; ETI: extra-
mural tumor invasion; MSI: microsatellite instability; MSS: microsatellite stable;
N: number; SD: standard deviation.
Not all sums of percentages equal 100% due to rounding of data.
aOther includes three low differentiated adenocarcinomas and one small cell/
neuroendocrine carcinoma.
bDefines the patients who were converted by neoadjuvant chemotherapy
from initially high-risk (needing adjuvant chemotherapy based on initial radi-
ology) to low-risk (not fulfilling the criteria for adjuvant chemotherapy).
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Tumor–stroma ratio
Tissue samples consisting of 5 mm thick H&E stained histo-
logic sections from the diagnostic biopsy and from the deep-
est invasive part in the bowel wall of the primary tumor
surgical specimen (slides used in routine pathology to deter-
mine T-category) were applied for TSR assessment. Areas
with the seemingly largest amount of stroma were selected
by conventional microscopy using a 2.5 or 5 objective.
Subsequently, an area containing both tumor and stromal tis-
sue in the vision-site was selected using a 10 objective.
Tumor cells were present at all borders of the image field
selected (north-east-south-west) for TSR semi-quantification.
TSR was estimated by one observer blinded to the clinical
data. Scoring percentages were semi-quantitatively reported
per tenfold (10%, 20%, 30%, etc.). For statistical analyses, stro-
mal ratio groups were divided into stroma-high (>50%, i.e.
TSR low) and stroma-low (50%, i.e. TSR high) as previously
determined to have maximum discriminative power in the
standard setting of upfront surgery [10].
Statistics
Differences between proportions were evaluated using
Fisher’s exact test. Disease free survival (DFS) was defined as
the time from operation to the first documented tumor
recurrence or death of any cause. Overall survival (OS) was
calculated as the time from operation until death of any
cause. All statistical calculations were performed using the
NCSS statistical software (NCSS Statistical Software, version
2007, Kaysville, UT, USA). p Values< .05 were considered sig-
nificant, and all tests were two-sided.
Results
Patient characteristics
Patient characteristics are summarized in Table 1. At the time
of data analysis, i.e. at a median follow-up of 5.3 years, dis-
ease recurrence had occurred in 15 patients.
Representative images of tumors with high stroma con-
tent (low TSR) and low stroma content (high TSR) are shown
in Figure 1.
Paired diagnostic biopsies and resected primary tumors
were not available for analysis in all patients. Assessment of
TSR was possible in 57 (88%) of the diagnostic biopsies and
62 (95%) of the surgically resected primary tumors. The distri-
bution is illustrated in Figure 2.
The relationship between TSR in the surgically resected
tumors and pathoanatomical characteristics is demonstrated
in Table 2. A low TSR was significantly (p< .03) associated
with perineural and vascular invasion, pT4 tumors, and lymph
node metastases.
Tumor–stroma ratio and effect parameters
A significant relationship was found between a low TSR in
the surgically resected primary tumor and lack of treatment
Figure 1. Representative images of a tumor with a low stroma content (high TSR) at (A) 25 and (B) at 100, and a tumor with a high stroma content (low TSR)
at (C) 25 and (D) at 100. The boxes outline the sections illustrated in (B) and (D), respectively. Tumor cells were to be present at all borders of the selected
image field (north-east-south-west).
530 T. F. HANSEN ET AL.
response assessed by TRG score (p¼ .0118) and risk group
conversion rate (p¼ .0009) (Table 3).
The potential challenge of comparing the two stromal-
based methodologies (i.e. TSR and TRG) is illustrated
in Figure 3.
Recurrence and prognosis
A significantly higher proportion of patients with low com-
pared to high TSR experienced disease recurrence; 13/29 and
2/33, respectively, p¼ .008. The positive and negative predict-
ive values of a low TSR were 45% (13/29) and 94% (31/33),
respectively. This relationship with recurrence is translated
into a significant difference in DFS and OS as illustrated in
Figure 4(A,B). The 5-year DFS rate in patients with a low TSR
was 55% compared to 94% in the group with a high TSR.
Discussion
Neoadjuvant chemotherapy represents a new treatment
approach in patients with locally advanced colon cancer. In
the present study, TSR was assessed the first time in the neo-
adjuvant setting demonstrating an association with clinically
relevant end points, and thus arguing for a role as a future
biomarker in this setting.
We analyzed TSR in the diagnostic biopsies and the surgi-
cally resected primary tumor. The diversity of the TSR score
in the biopsies was limited, in that 52 out of 57 biopsies
(91%) were scored as TSR high, preventing meaningful com-
parison with the clinical data. To the best of our knowledge,
this is the first report on TSR assessed in diagnostic biopsies
and it is likely that the limited tissue area available in the
biopsies is not adequate for the evaluation.
A low TSR in the surgically resected primary tumors was
detected in 47% of the patients, a ratio comparable to the
latest studies in the literature [4,5] although the initial studies
generally indicated a lower frequency (24–29%) of ‘low TSR’
[6–10]. A possible influence of neoadjuvant chemotherapy on
tumor tissue composition may explain, at least partly, this
difference.
Our results document a low TSR to be associated with a
significantly higher risk of vascular and perineural invasion
together with a higher T- and N-category compared to
tumors with a high TSR. These observations corroborate pre-
vious findings [4,6–8,10], and thus persist after neoadjuvant
chemotherapy.
We also investigated whether, in the surgically resected
primary tumor TSR was related to treatment effect.
Figure 2. Illustration of the sample distribution between biopsies and
resected tumors and the scoring results from the tumor–stroma ratio (TSR)
assessment.
Table 2. Relationship between tumor–stroma ratio and pathoanatomic charac-
teristics, N¼ 62.
After resection
Tumor–stroma ratio (TSR)
Characteristics Na Low/high p Value
Perforation
Yes 7 5/2 .237
No 55 24/31
Fixation
Yes 17 11/6 .096
No 45 18/27
Histology
Adenocarcinoma 48 22/26 1.000
Mucinous 10 4/6
Malignancy grade
1þ 2 37 16/21 .259
3 18 11/7
Perineural invasion
Yes 8 7/1 .021
No 54 22/32
Vascular invasion
Yes 18 15/3 .001
No 42 12/30
Tumor budding
Yes 9 5/4 .721
No 51 23/28
MSI status
MSS 43 21/22 .775
MSI 17 7/10
pT category
pT0–3 52 20/32 .004
pT4 10 9/1
pN category
pN0 39 13/26 .008
pN1–2 23 16/7
ECOG PS: Eastern Cooperative Oncology Group performance status; ETI: extra-
mural tumor invasion; MSI: microsatellite instability; MSS: microsatellite stable;
N: number; SD: standard deviation.
Not all sums of percentages equal 100% due to rounding of data.
p Values refer to Fisher’s exact tests.
aCases not evaluable regarding malignancy grade, vascular
invasion, tumor budding, and MSI status, and the four cases of ‘other’
histology (see Table 1) have been excluded from the analysis in this
table.
Table 3. Relationship between tumor–stroma ratio and effect of neoadjuvant
chemotherapy.
Tumor–stroma ratio (TSR)
Parameter Low High p Value
TRGa
1 0 0b
2 0 0
3 4 12 .0118
4 10 15
5 9 2
Risk group conversion
Yes 6 21 .0009
No 23 12
p Values refer to Fisher’s exact tests.
aTRG: tumor regression grade (according to Mandard et al.’s [14]).
bData on TRG was available from 53 patients, but one resected tumor was
scored TRG 1 with no adenocarcinoma cells present. Scoring of the TSR was
therefore not possible.
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A significant relationship was found between TSR and TRG
and the clinical down staging (from locally advanced tumor
before treatment to not fulfilling the requirements for adju-
vant treatment after the operation) indicating in both cases
poor response to neoadjuvant chemotherapy in patients with
a low TSR.
TRG and TSR do not reflect the same situation. TRG is
based on the whole tumor and TSR on a selected hotspot as
illustrated in Figure 3. The existence of only one carcinoma
focus in an otherwise fibrotic tumor, i.e. TRG 3, is not neces-
sarily reflected by a low TSR. Even though the rest of the
tumor is fibrotic, TSR may still be high. However, certain TRG
3 (and TRG 2) tumors may contain only very few scattered
carcinoma cells rendering TSR assessment inadequate.
Currently, there are no other studies addressing the possible
predictive value of the TSR in relation to chemotherapy in
colorectal cancer (CRC), but the present findings are plausible
given the association with T- and N-category at the time of
surgery.
We also found a convincing relationship between TSR and
disease recurrence, and consequently prognosis. Patients
with a high TSR had a very low risk of disease recurrence,
which was only seen in two of these patients. The result was
a negative predictive value of 94% indicating that in this set-
ting TSR assessment in the surgically resected primary tumor
may serve as a biomarker of clinical relevance. With only 6%
of the patients in this group experiencing disease recurrence,
one could argue that this group of patients should not be
treated with adjuvant chemotherapy at all. In comparison, a
recurrence rate of 6% is less than what is expected in stage I
colon cancer where adjuvant chemotherapy is not recom-
mended. Of the patients with a high TSR, 36% were not risk
group converted by neoadjuvant treatment and conse-
quently treated post-operatively with adjuvant chemother-
apy. The reason for high stroma content being prognostically
unfavorable is probably multifaceted, but increasing evidence
suggests cellular components of the stroma to be triggering
the epithelial–mesenchymal transition in the invasive zone of
the tumor and hence increasing the risk of metastatic
spread [15].
The current literature on the clinical potential of TSR
assessment in CRC is rather convincing and offers several
studies indicating a prognostic impact in stages I–III colon
cancer comparable to the present study in the neoadjuvant
setting. Additionally, the simplicity of semi-quantifying TSR,
freely available through routine diagnostics, strengthens its
potential as a biomarker. Results from large population based
cohorts, however, are still awaited. The same applies to stud-
ies on the possible predictive value and especially, on the
value of the TSR technique in rectal cancer. Validation of the
Figure 3. Tumor with minimal residual vital carcinoma and high tumor–stroma ratio (TSR) at (A) 25 and (B) 100. Even though most of the tumor is fibrotic (i.e.,
TRG equals score 2 or 3), TSR is still high in the predefined hotspot in the tumor after neoadjuvant chemotherapy.
Figure 4. Disease free survival (A) and overall survival (B) curves according to tumor–stroma ratio (TSR) in the surgically resected tumor. Upper curves represent
patients with a high TSR (stroma low, N¼ 33) and lower curves patients with a low TSR (stroma high, N¼ 29).
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current results is ongoing in a randomized phase III trial,
NeoCol (https://clinicaltrials.gov/ct2/show/NCT01918527?
term¼NeoCol&cond¼ColonþCancer&rank ¼1), offering neo-
adjuvant chemotherapy to patients with locally advanced
colon cancer.
In conclusion, this first study in the neoadjuvant setting
demonstrated that TSR assessed in the surgically resected pri-
mary tumor from patients with locally advanced colon cancer
treated with neoadjuvant chemotherapy provides prognostic
value and may serve as a relevant parameter in selecting
patients for post-operative treatment.
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